Free cash flow generation remains erratic, evidenced by a swing from a negative 8.7% margin in 2025Q4 to a positive 15.1% margin in 2026Q1.
| Cash from Operations | 490.31M | 404.22M | 367.34M | 63.7M | 92.61M |
| Operating CF Margin % | - | 7.64% | 8.98% | 2.05% | 3.82% |
| Operating CF Growth % | 0.95% | 10.04% | 476.7% | -31.22% | - |
| Net Income | 243.77M | 0 | 55.76M | 112.87M | 150.5M |
| Depreciation & Amortization | 61.03M | 0 | 40.81M | 25.63M | 22.31M |
| Stock-Based Compensation | 41.87M | 0 | 115.54M | 0 | 0 |
| Deferred Taxes | -10.61M | 0 | -44.48M | -9.92M | -1.92M |
| Other Non-Cash Items | 67.8M | 331.51M | 41.5M | 29.77M | 16.02M |
| Working Capital Changes | 86.45M | 72.71M | 158.22M | -94.66M | -94.29M |
| Change in Receivables | 8.48M | 14.43M | -116.45M | -179.94M | -114.62M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -19.68M | 14.86M | 33.4M | 33.37M | 32.81M |
| Cash from Investing | -374.97M | -264.02M | -442.68M | -172.79M | -75.32M |
| Capital Expenditures | -253.27M | 0 | -66.47M | -45.78M | -78.24M |
| CapEx % of Revenue | 4.66% | 1.99% | 1.63% | 1.47% | 3.23% |
| Acquisitions | 0 | - | - | - | - |
| Investments | 107.32M | 87.19M | 91.38M | 55.96M | 48.31M |
| Other Investing | 5.04M | -264.02M | -4M | 750K | 2.92M |
| Cash from Financing | -132.24M | -68.99M | 117.48M | 129.59M | 12.35M |
| Debt Issued (Net) | 0 | - | - | - | - |
| Equity Issued (Net) | 0 | 0 | 509.44M | 0 | 0 |
| Dividends Paid | 0 | 0 | -33.72M | -80.39M | -60.28M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -19.64M | -8.77M | -33.09M | 587K | 3.25M |
| Net Change in Cash | -16.89M | 71.21M | 42.14M | 20.5M | 29.64M |
| Free Cash Flow | 237.05M | 298.82M | 300.88M | 17.91M | 14.38M |
| FCF Margin % | 4.36% | 5.65% | 7.36% | 0.58% | 0.59% |
| FCF Growth % | -14.35% | -0.68% | 1579.46% | 24.59% | - |
| FCF per Share | 1.46 | 1.91 | 2.03 | 0.12 | 0.10 |
| FCF Conversion (FCF/Net Income) | 0.97x | 2.11x | 6.59x | 0.56x | 0.62x |
| Interest Paid | 32.42M | 40.51M | 48.25M | 50.56M | 25.91M |
| Taxes Paid | 83.69M | 84.05M | 107.83M | 60.01M | 42.55M |
Regulatory reimbursement policy shifts
As reported in recent financial statements, PACS Group exhibits significant volatility in its cash conversion, with the OCF/NI ratio swinging from a negative 0.06 in 2025Q4 to a high of 5.28 in 2025Q1, suggesting that reported net income is a poor proxy for actual cash generation.
The wide variance between net income and operating cash flow indicates that non-cash items and working capital fluctuations heavily distort the company's bottom-line performance. Investors should monitor whether this inconsistency stems from the timing of government reimbursements or the aggressive accounting treatment of newly acquired facility assets.
Based on the provided quarterly data, PACS Group's free cash flow trajectory remains highly erratic, with margins oscillating between a negative 8.7% in 2025Q4 and a positive 15.1% in 2026Q1, reflecting the capital-intensive nature of its rapid expansion strategy within the post-acute care sector.
The inability to maintain consistent positive free cash flow suggests that the company's growth model is highly sensitive to the timing of capital expenditures and facility-level operational performance. This instability warrants caution, as the company appears to rely on periodic cash inflows to offset the heavy costs associated with its acquisition-led growth.
According to the company's cash flow filings, capital expenditures have spiked significantly, reaching $114.3 million in 2025Q4, which represents a substantial 8.4% of revenue and indicates a heavy reinvestment requirement to maintain the clinical standards of its expanding portfolio of skilled nursing facilities.
The high capital intensity suggests that PACS must continuously invest in its physical infrastructure to remain competitive and compliant with regulatory standards. Analysts should investigate whether these expenditures are primarily for maintenance or if they represent necessary upgrades to integrate newly acquired facilities into the company's decentralized operating model.
As evidenced by the quarterly cash flow data, working capital changes have been a major source of volatility, with a $118.1 million inflow in 2026Q1 contrasting sharply with a $119.8 million outflow in 2025Q4, highlighting the company's susceptibility to shifts in billing cycles and collection timing.
The dramatic swings in working capital suggest that the company's liquidity is heavily dependent on the efficiency of its accounts receivable processes, particularly regarding Medicaid and Medicare reimbursements. Such fluctuations may indicate underlying challenges in managing the cash conversion cycle across a geographically dispersed and rapidly growing facility network.
Quick answers to the most common questions about buying PACS stock.
PACS Group, Inc. (PACS) generated $404.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
PACS Group, Inc. (PACS) generated $298.8M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
PACS Group, Inc. (PACS) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.